[ad_1]
Moderna Inc. has filed an initial public offering to sell for $ 500 million worth of shares, according to a statement Friday. Cambridge, Massachusetts, a biotech company, has named Morgan Stanley, Goldman Sachs and JP Morgan among the underwriters. The company plans to register on the Nasdaq under the symbol mRNA. Moderna has applied to be listed on the list of emerging growth companies facing fewer regulatory requirements. The company said that by September 30, it had raised more than $ 2.6 billion in financing and had cash, cash equivalents and investments of the order of 1, $ 2 billion. Moderna is developing messenger RNA-based "transforming drugs" for the treatment of infectious diseases, oncology, heart disease and rare genetic diseases, and its product portfolio includes cancer vaccines and influenza. "As we unlock the benefits of mRNA, we aim to treat as many diseases and reach as many patients as our technology, talents and financial resources allow," the statement said. Moderna recorded a net loss of $ 258 million, or $ 1.79 per share, in the first nine months of the year, compared to a loss of $ 228 million, or $ 1.63 per year. action, during the same period in 2017.
Have the latest news sent to your inbox. Subscribe to free e-mails from the MarketWatch newsletter. Register here.
Source link
